Johnson & Johnson’s (NYSE:JNJ) shares came under pressure, despite the fourth-quarter revenue beat and in-line 2026 guidance, mainly due to stock outperformance ahead of the print and developments around the talc litigation, according to Goldman Sachs.
The Analyst: Analyst Asad Haider reiterated a Buy rating, while raising the price target from $240 to $250.
The Thesis: The company already has a “sizable” revenue base of around $100 billion, and management expects double-digit topline growth by the end of this decade, higher than …